Abstract
Zaleplon (ZP) is a poorly water-soluble non-benzodiazepine hypnotic drug indicated for the short-term treatment of insomnia having a bioavailability of about 30%. The aim of the present study is to enhance the solubility and consequently the bioavailability of ZP using hydrotropic agents (HA). The solubility of ZP increased about 350- and 2000-fold, respectively, when 1 M of sodium benzoate and resorcinol were used as hydrotropic agents. The optimized mixed hydrotropic tablet formula (F5) composed of Resorcinol:Sodium benzoate microparticles prepared by solvent evaporation technique in a ratio of 4:1 w/w exhibits a significantly higher (p<0.05) in-vitro dissolution (Q5 min) of 31.7±0.11% after five minutes (Q5min) compared to 10.0 ± 0.10% for Sleep aid (5 mg) respectively. The optimized formula (F5) showed significantly higher (p<0.05) GABA concentration of 122.5±5.5 mg/mL in plasma compared to 118±1.00 and 27.8±1.5 mg/mL for Sleep aid (5 mg) and control taking only saline respectively suggesting a higher neuropharmacological effect of ZP following hydrotropic solubilization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
